Table 1 Baseline characteristics of clinical trial participants
From: Latent EBV enhances the efficacy of anti-CD3 mAb in Type 1 diabetes
Trial | Treatment arm (n) | Age (yrs, median (25th and 75th percentile) | EBV-seropositive (n, %) | CMV seropositive (n, %) |
|---|---|---|---|---|
TN10 | Teplizumab (44) | 14.6 (11.5, 22.8) | 18, 41% | 10, 23% |
Placebo (32) | 13.5 (10.8, 17.2) | 16, 50% | 7, 22% | |
ITN027AI (AbATE) | Teplizumab (52) | 11.8 (10.4,14.8) | 18 (35%) | 13 (25%) |
Control (23) | 12.0 (9.86, 15.7) | 8 (35%) | 4 (17%) |
